Our news

• NovaMedica and UNIPHARM to localize the production of Melaxen in Russia at the capacities of the R&D Center NovaMedica Innotech

  25 July 2019

  

  Russian pharmaceutical company NovaMedica and US-based Unipharm have launched a joint project to localize in Russia the production of Melaxen®, a drug that improves the sleep/wake cycle. Volumes are expected to reach hundreds of thousands of units per year, which will be sufficient to fully meet the needs of patients living in the territory of the EAEU.

• NovaMedica and Pharmsynthez agreed to establish full-cycle manufacturing of several in-demand products in Russia

  17 June 2019

  

  Russian pharmaceutical companies NovaMedica and Pharmsynthez started implementing a joint project to ensure access to a number of effective products, with the full manufacturing cycle localized in Russia, for Russian patients within 1.5-2 years. The products are in the anesthesiology and gastroenterology therapeutic areas, intended for both the hospital and commercial markets.

• PharmNews: NovaMedica Innotech debuts on CPhI

  09 October 2018

  

  The international exhibition CPhI has started in Madrid. And today NovaMedica Innotech is in our focus as the company that has made a bright debut at the exhibition. This Technological Center has launched in April 2017 and Moscow Mayor Sergei Sobyanin attended the opening ceremony.

• Five senior managers of NovaMedica were named among the nominees of the Top-1000 Russian Managers rating list for 2018

  25 September 2018

  

  In 2018 Alexander Kuzin, General Director of NovaMedica, was ranked among the most recognized senior managers in the pharmaceutical industry for the fifth time in the rating list. Maria Makarova, Deputy General Director and Vice-President for Finance; Marina Aivazova, Vice-President for Personnel Management and Administrative Matters; Yulia Sobakina, Vice-President for Commerce and Marketing; Tatiana Albaut, PR Director were also included into this competent rating.

• NovaMedica registered a unique for Russia and rare for the world drug for treatment of proctologic disease

  07 June 2018

  

  The Russian pharmaceutical company NovaMedica (RUSNANO's portfolio company) has registered a unique drug Fissario® for proctologic diseases treatment, based on a new mechanism of action not used in products currently on the market. This is the first drug developed within own R&D program of NovaMedica. It is planned that it will be available to patients already in 2019.

• NovaMedica, a portfolio company of RUSNANO, has concluded the biggest SPIC for creation of a greenfield pharmaceutical manufacturing facility in the pharmaceutical industry

  07 March 2018

  

  Russian pharmaceutical company NovaMedica (investment project of Rusnano), Ministry of Industry and Trade of the Russian Federation and Government of the Kaluga Region have concluded Special Investment Contract (SPIC). Denis Manturov, Minister of the Ministry of Industry and Trade, Anatoly Artamonov, Governor of the Kaluga Region, and Alexander Kuzin, General Director of NovaMedica, signed the contract. Arkady Dvorkovich, Deputy Chairman of the Government of the Russian Federation, and Anatoly Chubais, Chairman of the Executive Board of Managing Company “RUSNANO”, were present during the ceremony. SPIC envisages creation of a greenfield facility for manufacturing of sterile injectable dosage forms in the Kaluga region. During its implementation NovaMedica will invest more than three billion Rubles in the creation of the facility. Today this SPIC is the biggest one in the Russian pharmaceutical industry in terms of the amount of investments.   

• NovaMedica R&D Center will become a training facility for implementation of modern pharmaceutical technologies

  07 February 2018

  

  Russian pharmaceutical company NovaMedica (investment project of Rusnano) announces start of its cooperation in the area of transfer of knowledge and technologies between the R&D Center of NovaMedica Innotech and the German company Evonik – one of the leading companies in the international market of excipients manufacturing for the pharmaceutical industry. This partnership will result into creation of a training facility for transfer of competences in the area of pharmaceutical technologies at the premises of NovaMedica Innotech in Russia.

• R&D Center of NovaMedica has received GMP-Certificate from the Ministry of Industry and Trade of the Russian Federation

  26 December 2017

  

  Russian pharmaceutical company NovaMedica, investment project of Rusnano, informed about receipt of conclusion of the Ministry of Industry and Trade of the Russian Federation over compliance of the facility of the R&D Center of NovaMedica Innotech (subsidiary of NovaMedica) with the Russian standards of the Good Manufacturing Practice (GMP). The certificate issued basing on the integrated audit of the MIT RF commission, proves that the processes of development, manufacturing and quality control at NovaMedica Innotech are organized in accordance with the high standards of quality and manufacturing of tablets, soft and hard gelatin capsules and pellets at its manufacturing facilities meet the Russian GMP requirements. 

• Interdepartmental Commission has approved NovaMedica’s application for conclusion of SPIC aimed at creation of a new pharmaceutical manufacturing facility

  22 December 2017

  

  Russian pharmaceutical company NovaMedica (investment project of Rusnano) informed that it received approval of the Interdepartmental Committee (IDC) to conclude the Special Investment Contract (SPIC) within the investment project devoted to creation of a pharmaceutical plant for manufacturing of sterile injectable drug products in the Kaluga region. This is the first SPIC in the industry which is aimed at support of creation of a greenfield pharmaceutical facility. 

• NovaMedica appoints Yulia Sobakina as Commerce & Marketing Vice President

  02 November 2017

  

  Yulia Sobakina, who used to head Department of private label brands in the pharmacy chain Rigla of the Protek Group of Companies, has been appointed as Commerce & Marketing Vice President of the pharmaceutical company NovaMedica.